Caesars Entertainment Inc vs Viatris Inc — how do they compare? Caesars Entertainment Inc trades at $29.49 (market cap $6.02B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.3× Caesars Entertainment Inc's market cap, and Viatris Inc pays a 2.75% dividend while Caesars Entertainment Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Viatris Inc for 57 Days on average.
| CZR | VTRS | |
|---|---|---|
Market Cap | $6.02B | $20.03B |
Volume | 6,412,151 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $18.27 |
52-Week Low | $18.14 | $9.74 |
Typical Hold Time | 31 Days | 57 Days |
Enterprise Value | $29.91B | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Caesars Entertainment (CZR) trades at $29.54, showing minimal daily movement with a 0.15% gain. The stock faces bearish technical signals and has missed earnings expectations for three consecutive quarters, with negative profitability metrics including -3.99% net income margin. The pending $31 per share acquisition by Fertitta Entertainment provides a potential floor, while recent news highlights shareholder investigations into the deal's fairness. Cash flow trends show improvement with net cash flow narrowing from -$689M in 2022 to -$32M in 2025.
CZR presents a mixed outlook with acquisition upside limited to 5% from current levels, offset by fundamental challenges including consistent earnings misses and negative margins. Key risks include merger uncertainty and high debt load, while analyst sentiment remains cautious with 68% hold ratings. The stock offers speculative appeal for merger arbitrage but lacks organic growth catalysts.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →